Estefania Guerrero-Garcia

Sevilla, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Journal: Journal of translational medicine

Published: May 06, 2026

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Journal: Journal of translational medicine

Published: May 06, 2026

Metabolic and functional analysis including repetitive antigen stimulation provides a more accurate assessment for CAR-T cell product quality and long-term functionality.

Metabolic and functional analysis including repetitive antigen stimulation provides a more accurate assessment for CAR-T cell product quality and long-term functionality.

Journal: Journal of translational medicine

Published: December 01, 2025

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia.

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia.

Journal: Frontiers in immunology

Published: October 15, 2025

Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL.

Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL.

Journal: Stem cell research & therapy

Published: October 14, 2025

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Journal: Blood advances

Published: August 05, 2025

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Journal: Blood advances

Published: August 05, 2025

BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

Journal: Blood advances

Published: July 08, 2025

BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

Journal: Blood advances

Published: July 08, 2025

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

Journal: Journal of translational medicine

Published: April 07, 2025

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 09, 2024

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.

Journal: Frontiers in cell and developmental biology

Published: January 25, 2024

Showing 1-12 of 27

Last Updated: 09/26/2026